Recommendation of the President – Poltixa (apixaban)

On 23 February 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 29/2026 on the reimbursement of the medicinal product Poltixa (apixaban) for the indication: prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with at least one risk factor, such as a history of stroke or transient ischemic attack; age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA class ≥II)

Publication in Public Information Bulletin (BIP) >>